# OnCo record all-paediatric-high-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/all-paediatric-high-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "all-paediatric-high-risk" ;
  schema:name "High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)"@en ;
  schema:alternateName "NCI high-risk B-ALL"@en, "Very high-risk childhood ALL"@en, "Childhood T-cell ALL"@en, "T-ALL in children"@en ;
  schema:description "High-risk childhood leukaemia means a child aged ten or over, a very high white cell count, T-cell disease, spread to the brain or testes, or adverse genetics, and it is treated with longer and more intensive chemotherapy. Most children are still cured; the T-cell form gained the drug nelarabine after the AALL0434 trial, and cranial radiotherapy has been dropped for almost everyone."@en ;
  schema:url <https://onco.cc/cancers/all-paediatric-high-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia>, <https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/all-paediatric-standard-risk/>, <https://onco.cc/cancers/all-paediatric-ph-positive/>, <https://onco.cc/cancers/all-ph-like/>, <https://onco.cc/cancers/all-paediatric-relapsed/> ;
  onco:technologies <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd22/>, <https://onco.cc/targets/cd38/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/b-all-cytogenetic-risk/>, <https://onco.cc/terms/ph-like-all/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aall0232-larsen-jco-2016/>, <https://onco.cc/key-papers/paper-aall0434-nelarabine-t-all-dunsmore-jco-2020/>, <https://onco.cc/key-papers/paper-hunger-mullighan-all-children-nejm-2015/> ;
  onco:pipeline <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:standardOfCare <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/daunorubicin/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/mercaptopurine/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/leucovorin/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/nelarabine/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/thioguanine/>, <https://onco.cc/drugs/mercaptopurine/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> .